Myasthenia gravis (MG) is treated with a layered medication strategy that typically starts with a drug called pyridostigmine to manage symptoms, adds immunosuppressive medications to slow the underlying autoimmune attack, and in severe or refractory cases may now include newer biologic therapies that target specific parts of the immune system. No single pill cures MG, but the combination of available treatments means most people can achieve meaningful symptom control, and the landscape has changed substantially in just the past few years with the arrival of targeted biologics.
Why MG Requires Medication in the First Place
MG is driven by the immune system producing antibodies that attack the connection between nerves and muscles. In roughly three-quarters to nearly nine out of ten people with generalized MG, the culprit is antibodies directed at the acetylcholine receptor (AChR), the docking site where nerve signals tell a muscle to contract.1PubMed. Myasthenia gravis: the role of complement at the neuromuscular junction These antibodies damage the receptor in several ways: they speed up the rate at which receptors are broken down by cross-linking them together, they can physically block the receptor, and they trigger complement proteins that punch holes in the muscle-cell membrane.2PubMed Central. Mechanisms of acetylcholine receptor loss in myasthenia gravis The net result is fewer working receptors, weaker signals, and the hallmark symptoms of MG: drooping eyelids, double vision, difficulty swallowing, and limb weakness that worsens with activity.
A smaller group of patients has antibodies against a different target called muscle-specific kinase (MuSK), and an even smaller subset has antibodies against LRP4 or no detectable antibodies at all. This matters for treatment because some medications work better or worse depending on which antibody is involved.
Pyridostigmine and Symptomatic Relief
The first medication most people with MG encounter is pyridostigmine, an acetylcholinesterase inhibitor. It works by blocking the enzyme that normally breaks down acetylcholine in the junction between nerve and muscle. With more acetylcholine hanging around longer, the remaining receptors get a better chance of being activated, and muscle strength improves temporarily. Pyridostigmine is recommended as first-line therapy for MG despite a notable gap in the evidence: there have been few well-controlled clinical trials formally proving its benefit, though decades of clinical experience support its use.3PubMed. Treatment of myasthenia gravis: focus on pyridostigmine
For people with mild disease, particularly those whose symptoms are limited to the eye muscles, pyridostigmine alone may be enough.4PubMed Central. A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature The drug typically starts working within 30 to 60 minutes, peaks at a couple of hours, and wears off within four to six hours, so most people take it multiple times a day. Common side effects are gastrointestinal: cramping, diarrhea, and excess saliva. These are all caused by the same mechanism that helps the muscles, just acting on the gut and glands instead.
One important safety concept with pyridostigmine is the difference between a myasthenic crisis and a cholinergic crisis. Both can cause dangerous breathing difficulty, but for opposite reasons. A myasthenic crisis happens when the disease worsens and muscles become too weak to breathe. A cholinergic crisis happens when too much acetylcholinesterase inhibitor floods the system, essentially overloading the neuromuscular junction.5PubMed. Myasthenia gravis: myasthenia vs. cholinergic crisis Both are medical emergencies, and distinguishing between them matters because the treatments go in opposite directions.
Immunosuppressive Medications
When pyridostigmine alone is not enough, the standard next step is immunosuppression to tamp down the autoimmune process itself. Corticosteroids, usually prednisone, are the most common starting point. They work broadly to suppress immune activity, and many patients see improvement within weeks. However, corticosteroids carry a well-known paradox in MG: increasing doses can temporarily make symptoms worse before they get better. One study found this steroid-induced worsening occurred in about a quarter of patients, with higher initial doses and certain disease subtypes raising the risk.6PubMed. Predictive score for oral corticosteroid-induced initial worsening of seropositive generalized myasthenia gravis Because of this, neurologists often start corticosteroids at a low dose and increase gradually, especially for patients with more severe weakness.
Long-term corticosteroid use also brings a familiar burden of side effects: weight gain, bone thinning, elevated blood sugar, mood changes, and increased infection risk. These costs have pushed the field toward strategies that minimize steroid exposure, either by adding a steroid-sparing agent early or by tapering steroids as soon as another immunosuppressant takes hold.7PubMed Central. Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management
The two most commonly used steroid-sparing agents are azathioprine and mycophenolate mofetil. Both suppress the immune system by interfering with the proliferation of immune cells, though through somewhat different biochemical pathways. A head-to-head prospective study comparing the two found that mycophenolate had a numerical edge on quality-of-life improvement and clinical response rates, though the differences did not reach statistical significance. Adverse events were somewhat more common with azathioprine, occurring in about a third of patients compared with roughly a fifth on mycophenolate.8Lancet Neurology. Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study In practice, the choice between them often comes down to individual tolerability, cost, and physician experience. Other steroid-sparing options include methotrexate, cyclosporine, and tacrolimus, though these are used less frequently.
A key frustration with these conventional immunosuppressants is that they can take months to reach full effect. Azathioprine in particular may need six months or more before a patient notices substantial improvement. During that ramp-up, steroids often have to stay in the picture, which is why the long-term side-effect burden remains a real issue.
Targeted Biologics
The biggest shift in MG treatment over the past decade has been the arrival of biologic therapies that hit specific immune targets rather than broadly suppressing the whole system. Three main categories have emerged.
Complement inhibitors block part of the destructive cascade that AChR antibodies set in motion. Because these antibodies recruit complement proteins that form membrane attack complexes on the muscle surface, interrupting that cascade can protect the neuromuscular junction. Eculizumab was the first complement C5 inhibitor approved for generalized AChR-antibody-positive MG. Ravulizumab, a longer-acting version, followed, allowing dosing every eight weeks instead of every two.9PubMed. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis These drugs can produce rapid improvement, sometimes within weeks, which is a meaningful advantage over conventional immunosuppressants.
FcRn inhibitors represent an entirely different angle. The neonatal Fc receptor (FcRn) is a protein that rescues IgG antibodies from being degraded, essentially recycling them back into the bloodstream. By blocking FcRn, drugs like efgartigimod accelerate the clearance of all circulating IgG, including the pathogenic autoantibodies driving MG.10PubMed Central. FcRn Inhibition in Autoantibody-Mediated Autoimmune Diseases: From Broad Immunosuppression to Precision IgG Modulation Research has also suggested that efgartigimod may do more than simply lower antibody levels. It appears to promote the expansion of B cells with a regulatory phenotype, hinting at an immunoregulatory effect beyond straightforward IgG reduction.11PubMed Central. Immunoregulatory Effects of FcRn Inhibition by Efgartigimod in Myasthenia Gravis A New Mechanism of Action Beyond IgG Reduction Rozanolixizumab is another FcRn inhibitor that has been approved for MG in several markets.
B-cell depleting therapies, most notably rituximab, destroy the immune cells that produce antibodies. Rituximab is used off-label in MG but has shown particular promise in MuSK-antibody-positive disease, where uncontrolled studies have reported sustained benefit in patients who failed to respond to conventional immunosuppressants.12Autoimmunity Reviews. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase This makes sense biologically because MuSK antibodies are predominantly IgG4, a subclass that does not activate complement, so complement inhibitors are not useful for these patients. B-cell depletion attacks the problem at its cellular source instead.
Managing a Myasthenic Crisis
A myasthenic crisis, where weakness becomes severe enough to threaten breathing, requires rapid intervention that daily oral medications cannot provide. The two main rescue therapies are plasma exchange and intravenous immunoglobulin (IVIg). Plasma exchange physically removes circulating antibodies from the blood, while IVIg works through complex immunomodulatory mechanisms that are still not fully understood.
Both are effective, but they are not identical. A comparative study found that plasma exchange was associated with better ventilatory status at two weeks and better functional outcomes at one month. However, it came with a higher rate of complications.13PubMed. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis In practice, the choice between them often depends on what is available at a given hospital, whether the patient has venous access suitable for plasma exchange, and how quickly each can be started. Some patients also use these therapies on a recurring schedule to stay stable while other treatments ramp up.
An emerging area of research involves pharmacogenomics and IVIg. Genetic variation in the FcRn receptor, specifically a variant called the VNTR3 genotype, may affect how well a patient responds to IVIg by influencing how quickly their body recycles IgG. If validated in larger studies, this could eventually help neurologists predict who will benefit most from IVIg and adjust dosing accordingly.14Expert Review of Neurotherapeutics. Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis
The Role of Thymectomy
The thymus gland, located behind the breastbone, plays a role in training immune cells. In many MG patients, the thymus is abnormal, either enlarged or harboring a tumor called a thymoma. Surgical removal of the thymus, or thymectomy, has been used in MG management for decades, but it was not until 2016 that a randomized trial provided rigorous evidence for its benefit. That landmark study found that patients who had thymectomy plus prednisone had significantly better disease scores over three years compared with those on prednisone alone. The thymectomy group also needed substantially less prednisone and far fewer patients required additional immunosuppression with azathioprine or were hospitalized for flares.15PubMed. Randomized Trial of Thymectomy in Myasthenia Gravis
For patients with a thymoma, removal is considered essential regardless of MG severity. For non-thymoma patients, thymectomy is most clearly beneficial in younger adults with AChR antibodies. Research on late-onset MG, defined as onset after age 50, has been less settled, though a recent study found that even in this group, thymectomy was associated with more than a threefold increase in the probability of achieving disease remission compared with conservative management.16PubMed Central. Long-term effectiveness of thymectomy in late-onset myasthenia gravis Thymectomy is not typically recommended for patients with MuSK antibodies or those who are seronegative, as the evidence for benefit in those subgroups is thin.
Drugs That Can Make MG Worse
One of the trickier aspects of living with MG is that a surprisingly long list of common medications can worsen weakness or even unmask MG in someone who did not know they had it. This includes certain antibiotics, heart rhythm drugs, anesthetics, and neuromuscular blockers, all of which can interfere with the already-impaired neuromuscular transmission.17PubMed Central. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update
Some medications can even trigger MG that did not previously exist. Immune checkpoint inhibitors, which are increasingly used in cancer treatment, are among the most prominent offenders. By unleashing the immune system to fight tumors, they can also unleash autoimmunity. Other drugs associated with inducing de novo MG include penicillamine, certain tyrosine kinase inhibitors, and interferons.18PubMed Central. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update Patients with MG should carry a list of medications to avoid and make sure every prescribing physician, dentist, and anesthesiologist is aware of their diagnosis. The risk is highest in clinical settings like surgery, where several potentially problematic drugs may be used together.
When Standard Treatments Fail
A subset of MG patients does not respond adequately to the standard stepwise approach of pyridostigmine, steroids, and conventional immunosuppressants. International consensus definitions generally consider MG refractory when disabling symptoms persist despite prednisone and at least two immunosuppressants at appropriate doses and duration, or when treatment cannot be reduced without relapse, or when side effects are severe enough to prevent continued use.19PubMed Central. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
For these patients, the newer targeted biologics have been genuinely transformative. Complement inhibitors, FcRn antagonists, and B-cell depleting agents all offer alternative mechanisms that may succeed where conventional drugs failed. Even more experimental approaches are in development, including CAR T-cell therapy. An early-phase trial explored the use of RNA-based CAR T cells engineered to target B-cell maturation antigen (BCMA), a protein found on antibody-producing plasma cells. This approach, borrowed from cancer immunotherapy, aims to eliminate the specific cells responsible for making pathogenic antibodies.20The Lancet Neurology. Autologous anti-BCMA RNA CAR T cell therapy in patients with severe generalised myasthenia gravis (MG-001): a prospective, multicentre, open-label, phase 1b/2a study The use of RNA rather than the conventional DNA approach makes the CAR T cells transient, which could improve safety, though these results are very preliminary.
Side Effects, Pill Burden, and Sticking With Treatment
MG medications collectively carry a wide range of side effects that affect daily life in ways that go well beyond the disease itself. In structured patient surveys, reduced immunity, weight gain, blood clots, and diarrhea were rated among the least tolerable side effects. The impacts patients found most disruptive were sleep interference and reduced ability to participate in physical and social activities.21PubMed Central. Understanding side effects of therapy for myasthenia gravis and their impact on daily life
Adherence is a real problem. Several studies have found that the more pills a patient takes per day, the less likely they are to stay consistent with their regimen. This is especially relevant in MG, where someone might be taking pyridostigmine multiple times daily, a corticosteroid, a steroid-sparing immunosuppressant, and medications to manage side effects of those drugs. One study found that poor adherence was linked to lower educational attainment, longer disease duration, and a greater daily pill count, and that patients with poor compliance had worse quality of life and more neuropsychiatric symptoms.22PubMed. Medication adherence in patients with myasthenia gravis in Brazil: a cross-sectional study Increasing medication complexity from comorbid conditions compounds the problem, though the relationship between comorbidity burden and adherence is not straightforward and varies across different chronic diseases.23PubMed Central. The analysis of factors affecting medication adherence in patients with myasthenia gravis: a cross-sectional study
The Cost Problem With Newer Therapies
The arrival of targeted biologics has been a scientific triumph but an economic headache. Cost-effectiveness analyses have found that both eculizumab and efgartigimod, at their current prices, far exceed standard willingness-to-pay thresholds used in health economics, which raises serious questions about patient access.24PubMed Central. Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti-acetylcholine receptor antibody-positive generalized myasthenia gravis Eculizumab, for instance, has been one of the most expensive drugs in the world since its introduction for other rare diseases, and its MG indication did not change that price tag.
This is not just a problem in wealthy countries. In China, where biologic uptake for MG is growing, investigators have documented substantial barriers including high costs, limited insurance coverage, insufficient multicenter evidence from local populations, and uneven adoption by physicians across different regions.25Intractable & Rare Diseases Research. Current status and challenges of biologic targeted therapy for myasthenia gravis in China The practical result is that many patients who might benefit from these newer drugs remain on conventional therapies, with their longer onset times and heavier side-effect profiles, simply because cost is a barrier.
MG Medications During Pregnancy
Pregnancy in someone with MG requires careful balancing. The disease itself can fluctuate unpredictably during pregnancy, with some women improving, some worsening, and some staying stable. Several MG medications pose risks to a developing fetus, and some that are safe at one stage of pregnancy become problematic at another. Management needs to be individualized based on disease severity, which trimester the patient is in, and the safety profiles of available treatments.26PubMed Central. Management of myasthenia gravis during pregnancy
Pyridostigmine is generally considered safe during pregnancy and remains the cornerstone of symptomatic treatment. Corticosteroids are used when needed, though the risks of higher doses must be weighed against disease control. Mycophenolate mofetil is clearly contraindicated during pregnancy due to teratogenic effects and must be stopped well before conception. Azathioprine has a somewhat better safety profile in pregnancy, though the data are imperfect. IVIg and plasma exchange can both be used for acute exacerbations during pregnancy. The newer biologics have very limited pregnancy safety data, so decisions about using them require close discussion between the patient, their neurologist, and their obstetrician. Neonatal MG, where maternal antibodies temporarily affect the newborn, occurs in a minority of pregnancies and usually resolves within weeks, but the delivery team needs to be prepared for it.
How the First MG Drug Was Discovered
The story of MG medication begins in 1935, when a junior physician named Mary Walker tried giving physostigmine to a patient with MG. Physostigmine was already known as a treatment for curare poisoning, and Walker reasoned that if MG involved a similar kind of nerve-muscle blockade, the same drug might help. The improvement was dramatic and immediate, marking the first documented use of an acetylcholinesterase inhibitor for MG.27PubMed. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis Physostigmine was later replaced by pyridostigmine, which has a more favorable side-effect profile and longer duration of action, but the basic principle Walker identified, keeping acetylcholine around longer at the neuromuscular junction, remains the foundation of symptomatic MG treatment ninety years later. What has changed is everything layered on top of it: the immunosuppressants, the biologics, the surgical options, and the growing understanding that MG is not one disease but several, each potentially calling for a different combination of treatments.